PCP
AKBA icon

Proficio Capital Partners’s Akebia Therapeutics AKBA Stock Holding History

Proficio Capital Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
+12,725
New +$15.1K ﹤0.01% 688
2019
Q3 		– Sell
-377
Closed -$2K – 175
2019
Q2 		$2K Buy
+377
New +$2.15K ﹤0.01% 1499

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Proficio Capital Partners's AKBA Position: Q2 2026 in Review

Proficio Capital Partners opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 12,725 shares worth $14.5K. The stake represents ﹤0.01% of the portfolio and ranks #688 among its holdings. This is a return to the name: Proficio Capital Partners previously reported a position in AKBA as recently as Q2 2019.

Proficio Capital Partners first reported a position in AKBA in Q2 2019 and has held it in 2 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Proficio Capital Partners held 12,725 shares of Akebia Therapeutics worth $14.5K as of Q2 2026.
  • Akebia Therapeutics was a new Proficio Capital Partners position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Proficio Capital Partners's portfolio in Q2 2026, its #688 holding.
  • Proficio Capital Partners first reported a position in Akebia Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Proficio Capital Partners's 13F filing for Q2 2026, filed 17 Aug 2026.